(ABBI) Abraxis showed 60% gain in ABRAXANE in tumor response compared to Taxotere alone.
(AGO) Assured Guaranty filed to sell 1.5M shares for holder.
(AHO) Royal Ahold is in talks with private equity over potentially selling is US food service unit.
(BMET) Biomet Shares halted; still in talks to be acquired in auction process according to WSJ; deal has been in works for weeks though.
(BPA) BioSante received FDA approval on Bio-E-Gel (Elestrin) for hot flashes.
(BRKR) Bruker Bio filed to sell 10+ million shares of common stock.
(BUCY) Bucyrus pays $731M to acquire DBT GmbH in Germany.
(CMX) Caremark gets $26 Billion merger from Express Scripts, threatening the CVS deal.
(COCO) Corinthian Colleges Chairman is retiring.
(COP) ConocoPhillips noted as cheap compared to peers in barron’s.
(DALRQ) Delta will file restructuring plan to fight off a takeover.
(ENCY) Encysive hypertension pills are now available for sale in Germany.
(EXEL) Exelixis signed new collaborative pact with Bristol-Myers.
(H) Realogy gets $30.00 per share cash offer in a buyout from Apollo Management in a $9 Billion deal after debt assumptions.
(HET) Harrah’s board met over weekend to discuss the potential buyout from groups.
(ICFI) ICF International awarded $10M contract with EPA.
(ICOS) Icos gets $32 offer revised to $34.00 from Lilly.
(IDXX) IDEXX Labs is planning to acquire Osmetech’s critical care division for $44 million.
(IMAX) IMAX is trading down about 10% pre-market after the company decided to rule out a potential takeover, after down 60% that was obvious.
(JOYG) Joy Global $0.71 EPS vs $0.66e.
(LLL) L3 could face business hurdles after losing language training pact to DynCorp according to WSJ.
(LORL) Loral is paying $2.8 Billion to acquire BCE’s Telesat Canada, so forget about that IPO now. This is leveraged as LORL has a current market cap of $672M.
(MRD) MacDermid gets $35 buyout offer from a CEO-led group.
(NHO) Norsk Hydro trading up 25% as Statoil is buying the company’s oil and gas operations, effectively a merger.
(NFX) Newfield Exploration is cheap stock according to Barron’s.
(ORCL) Oracle reports after the close.
(OVEN) Turbo Chef shares could rise 40% according to Barron’s.
(POWI) Power Integrations gets NASDAQ delisting.
(RPRX) Repros Therapeutics says Proellex achieves statistically significant pain reduction in endometriosis trials; named new chief medical officer.
(SCS) Steelcase $0.22 EPS vs $0.19e.
(SGR) Shaw Group consortium with Westinghouse selected for new construction of nuclear plant in China.
(SNE) Sony may attempt to compete with iTunes according to WSJ note.
(SNY) Sanofi-Aventis said the FDA recommended against continued marketing of Ketek for axacerbated chronic bronchitis and sinusitis.
(SRA) Serono’s acquisition by Merck KGaA was approved by the European Commission.
(SWHC) Smith & Wesson is paying $102M to acquire Thomason/Center Arms and raised 2007 & 2008 guidance as result of additional company.
(TTEK) Tetra Tech wins $4M in reversed legal charge, will delay annual report and recognize charge of $200K.
(UBEY)YouBet.com filed to sell 6+ million shares.
(VZ) Verizon in pact with China Netcome and China telecom to construct and maintain the first next-generation optical cable underseas to directly link the US and China.
(WMG) Warner Music pays $73.5M for controlling stake in Roadrunner Music Group BV, a hard rock record label.
(ZVUE) Handheld Media paid $1M+ for YourDailyMedia video library.
Sponsored: Want to Retire Early? Here’s a Great First Step
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.